PegBio Co Ltd, a biopharmaceutical company in SIP, recently received the approval 　from National Medical Products Administration to put Pfizer’s new glucokinase activator (GKA) drug into clinical trials in the country. 

It is learnt that the company and Pfizer Inc, an over-160-year-old American pharmaceutical giant headquartered in New York City, launched collaboration in 2016 to bring the Pfizer clinical-stage type 2 diabetes treatment to the country.

The candidate, PB201 (known as PF-04937319 overseas), was developed to improve glycemic control in adults with type 2 diabetes when used in conjunction with metformin. Unlike other GKAs, it is capable of maintaining lower-glucose levels without resulting in hypoglycemia. It has gone through seven Phase I and two Phase II clinical tests among 600 patients overseas.